Clinical Trial Update: Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating everolimus after pazopanib in metastatic or advanced renal cell carcinoma has been terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: TERMINATED | Results posted: 2019-10-09